Abstract

Aim: In this study, we aimed to investigate the factors that may have the potential to predict pathological complete response (pCR) with platinum-based neoadjuvant chemotherapy (NAC) in non-metastatic muscle-invasive bladder cancer (MIBC).

Methods: Our study included 46 patients diagnosed with non-metastatic MIBC, who applied to Dicle University Medical Oncology Clinic between 2016-2019 years and received NAC. Age, gender, ECOG performance score, tumor grade, pathological tumor (pT) stage, clinical lymph node (cN) status, localization of the primary tumor in the bladder, presence of comorbid diseases, renal failure status, hydronephrosis, and NAC regimens were analyzed.

Results: Of the total 46 patients included in the study, 42 (81.3%) were male and 4 (8.7%) were female. The median age at diagnosis was 61.5 (34-77) years. In the group of patients aged <65 years, pCR was achieved in 9 patients (33.3%) and pCR was not achieved in 18 patients. The rate of pCR after NAC in the patient group aged <65 years was higher than in the age ≥65 group, which was statistically significant (p: 0.03). While the median disease-free survival (DFS) was not reached in the pCR arm, the median DFS was calculated as 26 months (95% CI: 4.6-47.3) in the non-pCR arm (Log Rank p=0.23). The mean overall survival (OS) value in the pCR arm was 126 months (95% CI: 106.5-145.4) and the mean OS value in the non-pCR arm was 53.5 months (95% CI: 44.2-62.9) (Log Rank p=0.05).

Conclusion: In our study, age <65 years was found to be an independent prognostic factor for pCR in the neoadjuvant treatment of non-metastatic MIBC. Mean OS was better in patients who achieved pCR.

Keywords: Bladder cancer, neoadjuvant chemotherapy, pathological complete response

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Urakçı Z, Ebinç S, Tunç S, Oruç Z, Küçüköner M, Kaplan MA, et al. Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer. Northwestern Med J. 2023;3(3):139-46. https://doi.org/10.54307/NWMJ.2023.41275

References

  1. Aveta A, Cacciapuoti C, Barone B, et al. The impact of meat intake on bladder cancer incidence: is it really a relevant risk? Cancers (Basel). 2022; 14(19): 4775. https://doi.org/10.3390/cancers14194775
  2. Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012; 53(8): 943-9. https://doi.org/10.1258/ar.2012.110700
  3. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9): 859-66. https://doi.org/10.1056/NEJMoa022148
  4. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29(16): 2171-7. https://doi.org/10.1200/JCO.2010.32.3139
  5. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48(2): 202-5. https://doi.org/10.1016/j.eururo.2005.04.006
  6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3. 2023.
  7. Miyagi H, Kwenda E, Ramnaraign BH, et al. Predicting complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Cancers (Basel). 2022; 15(1): 168. https://doi.org/10.3390/cancers15010168
  8. Russell B, Sherif A, Häggström C, et al. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scand J Urol. 2019; 53(4): 206-12. https://doi.org/10.1080/21681805.2019.1624611
  9. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 171(2 Pt 1): 561-9. https://doi.org/10.1097/01.ju.0000090967.08622.33
  10. Mi H, Bivalacqua TJ, Kates M, et al. Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. Cell Rep Med. 2021; 2(9): 100382. https://doi.org/10.1016/j.xcrm.2021.100382
  11. Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014; 83(1): 75-80. https://doi.org/10.1016/j.urology.2013.07.072
  12. Niegisch G, Albers P. Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer? Curr Opin Urol. 2011; 21(5): 434-9. https://doi.org/10.1097/MOU.0b013e328349582e
  13. Koie T, Ohyama C, Yamamoto H, et al. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Med Oncol. 2014; 31(5): 949. https://doi.org/10.1007/s12032-014-0949-9
  14. Mar N, Dayyani F. Management of urothelial bladder cancer in clinical practice: real-world answers to difficult questions. J Oncol Pract. 2019; 15(8): 421-8. https://doi.org/10.1200/JOP.19.00215
  15. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068-77. https://doi.org/10.1200/JCO.2000.18.17.3068
  16. Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015; 121(15): 2586-93. https://doi.org/10.1002/cncr.29387
  17. Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol. 2013; 189(5): 1682-6. https://doi.org/10.1016/j.juro.2012.10.120
  18. Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 2018; 4(11): 1535-42. https://doi.org/10.1001/jamaoncol.2018.3542
  19. Schinzari G, Monterisi S, Pierconti F, et al. Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: a prospective clinical trial based on cisplatin feasibility. Anticancer Res. 2017; 37(11): 6453-8. https://doi.org/10.21873/anticanres.12100
  20. Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012; 61(6): 1229-38. https://doi.org/10.1016/j.eururo.2011.12.010
  21. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014; 65(2): 350-7. https://doi.org/10.1016/j.eururo.2013.06.049
  22. Tse J, Ghandour R, Singla N, Lotan Y. Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts. Int J Mol Sci. 2019; 20(4): 793. https://doi.org/10.3390/ijms20040793
  23. Pokuri VK, Syed JR, Yang Z, et al. Predictors of complete pathologic response (pt0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Clin Genitourin Cancer. 2016; 14(1): e59-65. https://doi.org/10.1016/j.clgc.2015.09.013
  24. Harzstark A, Merchant M. Identifying predictors of pathologic complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. J Clin Oncol. 2019; 37(15 Suppl): e16015. https://doi.org/10.1200/JCO.2019.37.15_suppl.e16015
  25. Nielsen ME, Shariat SF, Karakiewicz PI, et al; Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007; 51(3): 699-706. https://doi.org/10.1016/j.eururo.2006.11.004